multitarget ad inhibitor-1

Multitarget AD inhibitor-1 is a reversible and selective inhibitor of butyrylcholinesterase (BuChE) with IC50 values of 7.22 μM for human BuChE (hBuChE) and 1.55 μM for equine serum BuChE (eqBuChE). It also exhibits inhibitory activity towards β-secretase (IC50 41.60 μM), amyloid β aggregation (IC50 3.09 μM), and tau aggregation. As a diphenylpropylamine derivative, Multitarget AD inhibitor-1 is promising for research into multifunctional, disease-modifying treatments for Alzheimer's disease.

SSZ is a multitarget inhibitor that addresses various pathological mechanisms in Alzheimers disease (AD). It targets acetylcholinesterase (acetylcholinesterase), butyrylcholinesterase (butyrylcholinesterase), β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), and γ-secretase (γ-secretase). In murine models, SSZ has been shown to improve Alzheimers disease and exhibit neuroprotective effects.